Friday, 14 Jun 2019

You are here

JAK Inhibition in Autoinflammatory Syndromes Interferonopathies

While many autoinflammatory syndromes are driven and managed with select inhibition of IL-1, IL-18 or IL-6, a subset are driven by type I interferon and are referred to as interferonopathies. These monogenic IFN–mediated disorders present in infancy with fevers, systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality.

Now researchers from the NIH have demonstrated that the use of the JAK inhibitor baricitinib, with IFN-blocking activity in vitro, leads to clinical disease improvement.

Researchers treated 18 patients, between 2011 and 2017, who were diagnosed with CANDLE (10 patients; chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures), 4 patients with SAVI (stimulator of IFN genes–associated [STING-associated] vasculopathy with onset in infancy), and 4 patients with other interferonopathies were enrolled in an expanded access program. 

Treatment for a mean of 3 years (1.5–4.9 years) led to symptom symptom score decreases from 1.3 (interquartile range [IQR], 0.93–1.78) to 0.25 (IQR, 0.1–0.63) (P < 0.0001) and reduced steroid use (14 patients) from 0.44 mg/kg/day to 0.11 mg/kg/day, and their IFN biomarkers decreased. Among the 10 CANDLE patients half achieved lasting clinical remission.

Three patients discontinued treatment because of lack of efficacy; 2 of these had genetically undefined conditions.

The most common adverse events were upper respiratory infections, gastroenteritis, and BK viruria and viremia.

These patients are usually poorly responsive to DMARDs or biologics targeting IL-1, TNF, and IL-6., In these studies the JAK1,2 inhibitor, baricitinib, improved inflammatory and IFN biomarkers in patients with the very rare disorders CANDLE, SAVI and other interferonopathies. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Upadacitinib Monotherapy in MTX-IR Rheumatoid Arthritis

Upadacitinib (UPA) is an oral, selective JAK1-selective inhibitor being developed for use in rheumatoid arthritis patients; Lancet has reported the SELECT-MONOTHERAPY trial showing that UPA is safe and effective in RA patients with an inadequate response to methotrexate (MTX).

This multicenter study randomized 648 patients, of whom 598 (92%) completed week 14.  

At week 14, an ACR20 responses were:

Predictors of Serious Infections with Rituximab

The risk of serious infectious events (SIE) with rituximab (RTX) is similar to that seen in other biologics (e.g., RA: 2% or 4.3/100PY), but with prolonged use the risk may change. Recent research says that low IgG levels, RTX induced neutropenia, prior SIE and comorbidities can significantly augment this risk. A retrospective longitudinal single center study of 700 rheumatic and musculoskeletal diseases (RMDs) treated monitored serum immunoglobulins (at baseline and 4–6 months after each cycle), clinical outcomes and SIE over time.

Nintedanib May Benefit Systemic Sclerosis Related Interstitial Lung Disease

The NEJM reports a randomized placebo controlled trial of nintedanib, a tyrosine kinase inhibitor, in systemic sclerosis patients with interstitial lung disease (ILD) resulted in less pulmonary decline, but had no effect on other features of systemic sclerosis. 

EMA Restricts Tofacitinib Dosing

The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency issued recommendations limiting the use of Xeljanz (tofacitinib) 10 mg twice daily in patients with ulcerative colitis in the EU. The new recommendations are temporary while PRAC undertakes a review of all available evidence on the safety and efficacy of tofacitinib. The review follows warnings of an increased risk of pulmonary embolism (PE) and death from the U.S. Food and Drug Administration based on Pfizer's large post-marketing safety study (in high risk rheumatoid arthritis patients with one or more underlying cardiovascular risk factors) wherein those receiving in tofacitinib 10 mg twice daily in study A3921133 had more PE and mortalities than comparator groups (tofacitinib 5 mg bid or adalimumab).

FDA Final Guidance on Interchangeability with Biosimilars

The FDA has published an industry guidance document to define interchangeability as regards to biosimilar use in the United States under section 351(k) of the Public Health Service Act (PHS Act) (42 U.S.C. 262(k)).